Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children

 Roche’s Evrysdi (risdiplam) Receives Health Canada’s Approval for Spinal Muscular Atrophy in Adults and Children

Roche Receives the US FDA’s EUA for cobas SARS-CoV-2 Test to Suspect COVID-19

Shots:

  • The approval is based on two studies i.e. FIREFISH & SUNFISH. The FIREFISH study involves assessing Evrysdi in infants aged 2-7mos. with symptomatic Type 1 SMA, and the SUNFISH study assesses Evrysdi in children & young adults aged 2-25yrs. with Type 2 or 3 SMA
  • Evrysdi demonstrated improvement in motor function, 29.3% of participants were able to sit without support for at least 5sec., 85.4% of participants shows event-free survival without permanent ventilation after 12 mos. of treatment
  • Evrysdi is a pre-mRNA splicing modifier of SMN2 designed to treat SMA in patients aged ≥2mos. and is the first at-home administered treatment for SMA

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Switzerland Global Enterprise

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post